Olympus CADDIE AI increases detection of hard-to-find colorectal lesions by 230% in EAGLE Trial. Cloud-based system improves cancer prevention without disruptingOlympus CADDIE AI increases detection of hard-to-find colorectal lesions by 230% in EAGLE Trial. Cloud-based system improves cancer prevention without disrupting

Cloud-Based AI System Shows Promise in Detecting High-Risk Colorectal Lesions, Study Finds

3 min read

The EAGLE trial, a multicenter randomized controlled study published in npj Digital Medicine, indicates that cloud-deployed artificial intelligence can help endoscopists detect lesions most critical for preventing progression to colorectal cancer. The study evaluated the CADDIE™ device, the first cloud-based Computer-Aided Detection application for real-time polyp detection during colonoscopy that is both FDA-cleared and CE-marked.

Conducted across eight centers in four European countries, the trial involved 841 patients and 22 endoscopists performing screening and surveillance colonoscopies. Patients were randomized to standard colonoscopy or CADDIE-assisted colonoscopy. The primary analysis revealed that use of the CADDIE application was associated with a 7.3% absolute increase in adenoma detection rate compared to standard colonoscopy.

Significant relative increases in lesions detected per colonoscopy were observed for clinically relevant lesion subtypes: 93% for large adenomas (>10 mm), 57% for non-polypoid adenomas, and 230% for sessile serrated lesions (SSLs). SSLs are high-risk lesions whose detection is critical to reducing the risk of post-colonoscopy colorectal cancer, according to research published in Gastrointestinal Endoscopy and The Lancet Gastroenterology & Hepatology.

The CADDIE application is trained on a dataset enriched in clinically relevant and hard-to-detect lesions, including flat sessile serrated lesions and large polyps. Lesions with sessile or flat morphology are difficult to detect and can harbor clinically relevant pathology. The ability to reliably detect SSLs is increasingly viewed as a critical quality consideration in colonoscopy, as noted in quality indicator guidelines published in Gastrointestinal Endoscopy.

The system demonstrated real-time performance and operational efficiency across diverse testing environments. Cloud deployment offers hospitals flexibility, reducing reliance on hardware and enabling subscription-based procurement models. This approach can democratize access to advanced AI tools and lays the foundation for future AI applications in endoscopy.

‘This study marks a pivotal shift in the clinical translation of AI-assisted endoscopy,’ said Rawen Kader, Principal Investigator of the EAGLE Trial and GI Researcher at University College London. ‘Cloud deployment can remove hardware barriers and give hospitals access to the latest AI innovations, which has the potential of improving detection of the lesions that matter most for reducing colorectal cancer risk.’

For complete access to the EAGLE Trial study, visit https://doi.org/10.1038/s41746-025-02270-1. The gastroenterologist is responsible for reviewing CADDIE suspected polyp areas and confirming the presence or absence of a polyp based on their own medical judgment. CADDIE is not intended to replace a full patient evaluation, nor is it intended to be relied upon to make a primary interpretation of endoscopic procedures, medical diagnosis, or recommendations of treatment.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cloud-Based AI System Shows Promise in Detecting High-Risk Colorectal Lesions, Study Finds.

The post Cloud-Based AI System Shows Promise in Detecting High-Risk Colorectal Lesions, Study Finds appeared first on citybuzz.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Tesla Stock Forecast: Will $1.25T SpaceX-xAI Merge Boost TSLA?

Tesla Stock Forecast: Will $1.25T SpaceX-xAI Merge Boost TSLA?

Tesla shares closed at $421.96 as of February 4, holding flat while broader markets slipped. The muted move came as investors digested reports that SpaceX and xAI
Share
Coinstats2026/02/04 19:10
Moku Pledges $1M to Launch Grand Arena Season One, a 24/7 AI-Athlete Fantasy Platform

Moku Pledges $1M to Launch Grand Arena Season One, a 24/7 AI-Athlete Fantasy Platform

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
Share
Blockchainreporter2025/09/22 22:20
Long-Awaited NikeSKIMS Launches To Reignite Nike’s Women’s Business

Long-Awaited NikeSKIMS Launches To Reignite Nike’s Women’s Business

The post Long-Awaited NikeSKIMS Launches To Reignite Nike’s Women’s Business appeared on BitcoinEthereumNews.com. Topline After delays due to product issues in its scheduled May release, the first NikeSKIMS activewear collections – the strategic partnership between the sportswear giant and Kim Kardashian’s $4 billion disruptive shapewear venture – will launch on both companies’ websites and in select Nike and SKIMS stores this Friday, September 26. Serena Williams for NikeSKIMS Courtesy of Nike Key Facts NikeSKIMS’ first outing will include three core activewear collections, along with four seasonal collections, all designed to support women with high-performance fabrication expected from Nike and the body-conscious styling SKIMS is known for. The introductory offering features 58 items in neutral colorways that can be combined into more than 10,000 different looks suited for an intense gym workout or a coffee run. An all-star cast of 50 elite female athletes star in the “Bodies at Work” release video, including Jordan Chiles, Romane Dicko, Beatriz Hatz, Chloe Kim, Nelly Korda, Sha’Carri Richardson, Madisen Skinner and Serena Williams, as well as Kardashian and members of UCLA and USC women’s teams. Prices will range from $38 for a bra to $128 for footed leggings, with the sweet spot for the collection in the $50 to $70 range, about even or slightly below the list price of premium activewear brands such as Lululemon and Alo Yoga. Crucial Quote “NikeSKIMS is more than a collaboration – It’s a new brand redefining activewear. With this launch, we are establishing a platform to grow NikeSKIMS, reach consumers worldwide and set a new benchmark for how activewear is experienced across retail, digital and cultural touch points,” said Jens Grede, SKIMS’ co-founder and CEO, in a statement. Key Background Nike has a lot riding on the success of the SKIMS-style meets Nike-function launch of NikeSKIMS. Nike brand revenues dropped 9% to $44.7 billion in fiscal year ended May 31…
Share
BitcoinEthereumNews2025/09/23 22:30